HCV - Genotype



•Early Predictors of Anemia in Genotype 1 HCV Patients Treated with Pegasys plus Ribavirin  11/07/06
•More Frequent Dosing of Pegasys/Ribavirin Improves SVR Rate in Prior Non-responder Genotype 1 HCV Patients with Severe Fibrosis  11/07/06
•Utility of Virological Response at Weeks 4 and 12 in the Prediction of SVR in Genotype 2/3 Patients: ACCELERATE Trial Results  11/07/06
•A la Carte Therapy More Cost-effective than Standard Combination Therapy for Treatment-naive Patients with Chronic Hepatitis C  11/07/06
•PegIntron plus Ribavirin in HCV Genotype 1 Patients with Slow Virological Response: Analysis of Early Enrollers in the SUCCESS Study  11/07/06
•Treatment Extension to 72 Weeks of PegIntron plus Weight-based Ribavirin Improves SVR Rates in Difficult-to-Treat Slow Responders with Genotype 1  11/03/06
•Risk Factors for Relapse in Patients with High Viral Load and Genotype 3 Hepatitis C in the WIN-R Trial  11/03/06
•Pegasys plus Ribavirin for 16 versus 24 Weeks in Patients with HCV Genotype 2  11/03/06
•

Higher Fixed Doses of Both Pegasys and Ribavirin May Benefit Difficult-to-Cure Genotype 1 Patients with High Viral Load and Above Average Body Weight  11/03/06

•Pegylated Interferon alfa-2b Plus Ribavirin in Patients With Genotype 1 Chronic Hepatitis C With a Slow Virologic Response: A Preliminary Report of the SUCCESS Study
M Buti and others. Poster #404





Google_______________


 

 

 

 

 

 

 

 

 

 

 

 

 

 


Conference
Main Page

Hepatitis C
FDA-Approved
Treatments

Monotherapies
Intron A
Roferon
Infergen
Pegasys
PEG-Intron

Combination
 Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin

Hepatitis B
FDA-Approved
Treatments

Baraclude
 Epivir-HBV
 Hepsera
 Intron A
 Pegasys
 Tyzeka